Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
Influenza is a common viral respiratory infection that is associated with significant morbidity. Oseltamivir (Tamiflu) is a neuraminidase inhibitor-a new class of antiviral treatment for influenza where efficacy and safety has been established but cost-effectiveness is unknown. ⋯ Oseltamivir for treatment of patients with ILI is potentially cost-effective if clinical diagnostic specificity for influenza observed in clinical trials is applicable to routine practice. More population-based information on the prevalence of influenza among early (<48 hours) presenters with ILI would be valuable.
-
Comparative Study
Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children.
The purpose of this study was to compare health-care resource utilization and outcomes among children treated for low-risk febrile neutropenia (FN) in a hospital-based setting with those treated in a home-care-based setting. ⋯ We found that management of low-risk FN in a home-care-based setting was associated with significantly lower median total charges with no differences in outcome.